Nausea, vomiting, flushing, tachycardia, and severe hypotension have been reported following alcohol ingestion during griseofulvin therapy.
Source: NLP:griseofulvin
Griseofulvin Interactions
Brand names: Griseofulvin
Tubulin Inhibiting Agent
Route: Oral
Contraindications
CONTRAINDICATIONS Griseofulvin is contraindicated in patients with porphyria or hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin. Griseofulvin may cause fetal harm when administered to a pregnant woman. Two published cases of conjoined twins have been reported in patients taking griseofulvin during the first trimester of pregnancy, therefore, griseofulvin is contraindicated in women who are or may become pregnant during treatment. Women taking estrogen-containing oral contraceptives may be at increased risk of becoming pregnant while on griseofulvin (see also PRECAUTIONS, Drug Interactions ). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Although no direct causal relationship has been established, spontaneous abortion has been reported rarely coincident with the use of griseofulvin. Note: The Maximum Recommended Human Dose (MRHD) was set at 500 mg/day for the multiple of human exposure calculations performed in this label. If higher doses than 500 mg/day were used clinically, then the multiple of human exposure would be correspondingly reduced for that dose. For example, if a 1000 mg/day dose was administered to an individual, then the multiple of human exposure would be reduced by a factor of 2. Griseofulvin has been shown to be embryotoxic and teratogenic in pregnant rats when given at a daily oral dose of 250 mg/kg/day [4X the Maximum Recommended Human Dose (MRHD) based on Body Surface Area (BSA)]. Griseofulvin also has been shown to be embryotoxic and teratogenic in pregnant cats treated weekly with griseofulvin at doses of 500 to 1000 mg/week. There are reports of teratogenicity in a Golden Retriever when doses of 750 mg/day [1.2X the MRHD based on BSA] were administered for four weeks prior to and throughout the pregnancy, and in a study in which beagles were administered 35 mg/kg/day [1.9X the MR
Pregnancy & Breastfeeding
Pregnancy: Teratogenic Effects: Pregnancy Category X: See CONTRAINDICATIONS and PRECAUTIONS, Drug Interactions . Nursing Mothers: It is not known if griseofulvin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for griseofulvin in animal studies (see PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility ), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use: Safety and effectiveness in pediatric patients 2 years of age and younger have not been established. Safety in pediatric patients older than 2 years of age at dosages greater than 10 mg/kg daily has not been established.
30 interactions on record
May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabolism of contraceptive steroids.
Source: NLP:norethindrone
Concomitant use may enhance phototoxic reaction to photodynamic therapy.
Source: NLP:aminolevulinic acid hydrochloride
Griseofulvin + BarbituratesModerate
Barbiturates usually depress griseofulvin activity by decreasing plasma levels, requiring dosage adjustment of griseofulvin.
Source: NLP:griseofulvin
Griseofulvin + CyclosporineModerate
Griseofulvin may reduce cyclosporine levels, resulting in decreased pharmacologic effects.
Source: NLP:griseofulvin
Possible association with reduced efficacy and breakthrough bleeding, though less marked than with rifampin.
Source: NLP:desogestrel and ethinyl estradiol and ethinyl estradiol
Induces CYP3A4 enzyme, may decrease effectiveness of COCs or increase breakthrough bleeding.
Source: NLP:drospirenone and ethinyl estradiol
Griseofulvin + Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate CalciumModerate
May decrease the effectiveness of hormonal contraceptives or increase breakthrough bleeding through CYP3A4 enzyme induction.
Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium
Enzyme inducer that may decrease effectiveness of COCs or increase breakthrough bleeding. Use back-up contraception.
Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Griseofulvin + EstrogensModerate
Griseofulvin may enhance hepatic metabolism of estrogens, reducing effectiveness and causing menstrual irregularities. Alternate birth control may be indicated.
Source: NLP:griseofulvin
Possible association with reduced contraceptive efficacy, though less marked than rifampin.
Source: NLP:ethynodiol diacetate and ethinyl estradiol
Griseofulvin + EtonogestrelModerate
May decrease plasma concentrations of etonogestrel and diminish contraceptive effectiveness or increase breakthrough bleeding.
Source: NLP:etonogestrel
CYP3A4 enzyme inducer that may decrease plasma concentrations of etonogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:etonogestrel and ethinyl estradiol
Griseofulvin induces CYP3A4 and may decrease plasma concentrations of COCs, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:levonorgestrel and ethinyl estradiol and ferrous bisglycinate
Griseofulvin induces CYP3A4 enzymes, potentially decreasing contraceptive effectiveness and increasing breakthrough bleeding.
Source: NLP:norethindrone and ethinyl estradiol and ferrous fumarate
Enzyme inducer that may decrease plasma concentrations of contraceptive hormones and reduce effectiveness of hormonal contraceptives or increase breakthrough bleeding.
Source: NLP:levonorgestrel / ethinyl estradiol and ethinyl estradiol
May decrease effectiveness of medroxyprogesterone acetate through enzyme induction. Counsel use of back-up or alternative contraception.
Source: NLP:medroxyprogesterone acetate
Enzyme inducer that may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.
Source: NLP:norelgestromin and ethinyl estradiol
CYP3A4 inducer that may decrease the effectiveness of COCs or increase breakthrough bleeding.
Source: NLP:norethindrone acetate and ethinyl estradiol, and ferrous fumarate
Pregnancy while taking combined oral contraceptives has been reported with griseofulvin, though clinical studies have not demonstrated consistent effects on synthetic steroid concentrations.
Source: NLP:norethindrone acetate and ethinyl estradiol
Enzyme inducer that may decrease plasma concentrations of norethindrone and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:norethindrone and ethinyl estradiol
CYP3A4 enzyme inducer that may decrease plasma concentrations of COCs and potentially diminish contraceptive effectiveness or increase breakthrough bleeding.
Source: NLP:norgestimate and ethinyl estradiol
Griseofulvin may enhance metabolism of the estrogen component, reducing contraceptive effectiveness and causing menstrual irregularities.
Source: NLP:griseofulvin
Barbiturates interfere with absorption of orally administered griseofulvin, decreasing blood levels. Concomitant administration should preferably be avoided.
Source: NLP:pentobarbital sodium
Griseofulvin + PhenobarbitalModerate
Phenobarbital interferes with absorption of orally administered griseofulvin, decreasing blood levels. Concomitant administration should preferably be avoided.
Source: NLP:phenobarbital
Phenobarbital appears to interfere with absorption of orally administered griseofulvin, decreasing its blood level. Concomitant administration should preferably be avoided.
Source: NLP:phenobarbital sodium
Griseofulvin + Porfimer SodiumModerate
Concomitant use may increase the risk of photosensitivity reaction. Avoid concomitant use with other photosensitizing agents.
Source: NLP:porfimer sodium
Griseofulvin + SalicylatesModerate
Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly.
Source: NLP:griseofulvin
Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.
Source: NLP:verteporfin for injection
Griseofulvin + WarfarinModerate
Griseofulvin decreases the activity of warfarin-type anticoagulants, requiring dosage adjustment of the anticoagulant during and after griseofulvin therapy.
Source: NLP:griseofulvin